call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Gcc Erectile Dysfunction Drugs Market
Inquire Before Buying Request for Sample

Gcc Erectile Dysfunction Drugs Market

Home Healthcare And Pharmaceutical Gcc Erectile Dysfunction Drugs Market

SPECIAL OFFER : 25% Super Discount For All !

GCC Erectile Dysfunction Drugs Market, By Product (Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Country (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Trend Analysis, Competitive Landscape & Forecast, 2019–2029

  • Published Date: September 2023
  • Report ID: BWC23714
  • Available Format: PDF
  • Page: 200

Report Overview

Increasing awareness about the drugs for the treatment of erectile dysfunction (ED) and growing prevalence of ED driven by poor lifestyle choices and stress are expected to boost the expansion of GCC Erectile Dysfunction Drugs Market during the forecast period between 2023 and 2029.

GCC Erectile Dysfunction Drugs Market - Industry Trends & Forecast Report, 2029

GCC erectile dysfunction drugs market size was estimated to be worth USD 68.83 million in 2022. During the forecast period between 2023 and 2029, the GCC erectile dysfunction drugs market size is projected to grow at a CAGR of 8.98%, reaching a value of USD 115.32 million by 2029. Major growth factors for the GCC erectile dysfunction drugs market include the rising prevalence of erectile dysfunction owing to the poor lifestyle adopted by the male population along with increasing awareness and acceptance of the disease and its treatment.

GCC Erectile Dysfunction Drugs Market

GCC Erectile Dysfunction Drugs Market – Overview

According to Mayo Clinic, erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. ED can have a variety of reasons and can signal underlying health issues including diabetes, high cholesterol, or other conditions like heart disease. Drugs used to treat erectile dysfunction work by boosting blood flow to the penis, which aids in achieving and maintaining an erection. The most often recommended treatments for ED are sildenafil (Viagra) and tadalafil (Cialis), which also have favorable clinical outcomes.

GCC Erectile Dysfunction Drugs Market

Growth Drivers

Rising Prevalence of Erectile Dysfunction

According to a study published on NCBI on the prevalence of erectile dysfunction (ED) in Arab countries, overall, 50.8% of patients experienced premature ejaculation, 7.6% had reduced sexual desire, and 92.6% had ED. Furthermore, 80% of the patients had biological reasons for ED, while 20% had psychogenic causes. About 50% of the patients had severe ED, 40% had moderate ED, and 10% had mild ED. As a result, the pharmaceutical companies are engaging in extensive R&D activities to launch erectile dysfunction drugs in the GCC market, which is anticipated to drive the overall market growth.

Restraints

Negative Side Effects of Erectile Dysfunction Drugs

The consumption of erectile dysfunction drugs regularly does not generally pose any health risks or side effects. However, some people with certain medical conditions, such as hypotension and inherited eye diseases like retinitis pigmentosa or leukemia, are advised to avoid ED drugs. Erectile dysfunction pills should also be avoided by those who have specific cardiac diseases that are deemed too harmful for sexual activity and by those who use certain pharmaceutical classes, such as alpha-blockers and antihypertensives. This may act as a major restraining factor for the GCC erectile dysfunction drugs market.

Impact of COVID-19 on the GCC Erectile Dysfunction Drugs Market

The unprecedented COVID-19 pandemic presented new growth opportunities for the GCC dysfunction drugs market. Several studies revealed that the COVID-19 infection caused a 20% increase in the prevalence of erectile dysfunction among men. According to an article published in the International Journal of Impotence Research, the psychological burden of the COVID-19 infection and direct testicular damage influenced the chances of ED among men during the pandemic. As a result, the demand for erectile dysfunction drugs spiked in the GCC countries during the pandemic, increasing the overall market growth.

GCC Erectile Dysfunction Drugs Market

Segmental Coverage

GCC Erectile Dysfunction Drugs Market – By Product

Based on product, the GCC erectile dysfunction drugs market is divided into Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), and others. Viagra (sildenafil citrate) holds the highest share in the GCC erectile dysfunction drugs market. It boosts blood flow to the penis when sexually stimulated and assists in maintaining an erection by relaxing a few smooth muscles. As a result, pharmaceutical companies are launching Viagra pills in the market to tap into the growing market opportunities, propelling the overall market growth.

GCC Erectile Dysfunction Drugs Market – By Distribution Channel

Based on the distribution channel, the GCC erectile dysfunction drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounts for the highest share of the market. The growth of the segment is mainly attributed to the easy accessibility to the drugs in the pharmacy stores. Patients who are conscious about buying erectile dysfunction medications and other sexual health goods find retail pharmacy stores convenient to buy such drugs. However, online pharmacies are projected to register the highest CAGR during the forecast period.

GCC Erectile Dysfunction Drugs Market Size

GCC Erectile Dysfunction Drugs Market – By Country

The GCC erectile dysfunction drugs market covers six countries in the region: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE). Saudi Arabia dominates the GCC erectile dysfunction drugs market owing to the high prevalence of ED in the country. According to a paper published by National Center for Biotechnology Information, the incidence of ED is 10.53% among married Saudi men. Age, a pre-existing medical condition, physical activity, and a lesser level of education are risk factors for ED among men in Saudi Arabia.

Competitive Landscape

Major players operating in the GCC erectile dysfunction drugs market include Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, and Bayer AG.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In August 2023 - Labatec Pharma, a pharmaceutical company based in Switzerland, received regulatory approval to release and commercialize MED3000, Futura’s tropical, gel-based ED treatment in the Kingdom of Saudi Arabia.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period– 2023–2029

Facts Covered

Revenue in USD Million

Market Coverage

Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE

Product/ Service Segmentation

Product, Distribution Channel, Region

Key Players

Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, Bayer AG

 

By Product

  • Viagra (sildenafil citrate)

  • Cialis (tadalafil)

  • Levitra/Staxyn (vardenafil)

  • Stendra/Spedra (avanafil)

  • Zydena (Udenafil)

  • Vitaros (alprostadil cream)

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Country

  • Bahrain

  • Kuwait

  • Oman

  • Qatar

  • Saudi Arabia

  • United Arab Emirates

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  GCC Erectile Dysfunction Drugs Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Growth in Embracing Poor Lifestyle Choices
        2. Increasing Incidence of Diseases
        3. Rising Prevalence of Erectile Dysfunction
      2. Restraints
        1. Negative Side Effects of Erectile Dysfunction Drugs
        2. Low Awareness associated with Erectile Dysfunction Drugs
      3. Opportunities
        1. Increased Pharmaceutical Manufacturing
        2. Increasing Investments in R&D and Clinical Trials
      4. Challenges
        1. Increasing Availability of Counterfeit Erectile Dysfunction Medicines
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. GCC Erectile Dysfunction Drugs Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share and Forecast
      1. By Product
        1. Viagra (sildenafil citrate)
        2. Cialis (tadalafil)
        3. Levitra/Staxyn (vardenafil)
        4. Stendra/Spedra (avanafil)
        5. Zydena (udenafil)
        6. Vitaros (alprostadil cream)
        7. Other
      2. By Distribution Channel
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      3. By Country
        1. Bahrain
        2. Kuwait
        3. Oman
        4. Qatar
        5. Saudi Arabia
        6. United Arab Emirates
  5. Bahrain Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
      3. By End User
      4. By Technique
  6. Kuwait Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
  7. Oman Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
  8. Qatar Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
  9. Saudi Arabia Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
  10. United Arab Emirates Erectile Dysfunction Drugs Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Product
      2. By Distribution Channel
  11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. GCC Erectile Dysfunction Drugs Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  12. Impact of Covid-19 on GCC Erectile Dysfunction Drugs Market
  13. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Pfizer
    2. Eli Lilly and Company
    3. Teva
    4. Sun Pharmaceutical
    5. Lupin Limited
    6. Glenmark Pharmaceuticals Limited
    7. Cipla Ltd
    8. Sanofi
    9. Apricus Biosciences
    10. Bayer AG
    11. Other Prominent Players
  14. Key Strategic Recommendations
  15. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Country
    5.    Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

 

Figure 1       GCC Erectile Dysfunction Drugs Market Segmentation

Figure 2       GCC Erectile Dysfunction Drugs Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2022

Figure 4       GCC Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019–2029

Figure 5       GCC Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019–2029

Figure 6       GCC Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019–2029

Figure 7       GCC Erectile Dysfunction Drugs Market Share, By Country, By Value, 2019–2029

Figure 8       Bahrain Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 9       Bahrain Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 10     Bahrain Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Figure 11     Kuwait Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 12     Kuwait Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 13     Kuwait Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Figure 14     Oman Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 15     Oman Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 16     Oman Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Figure 17     Qatar Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 18     Qatar Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 19     Qatar Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Figure 20     Saudi Arabia Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 21     Saudi Arabia Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 22     Saudi Arabia Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Figure 23     United Arab Emirates Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Figure 24     United Arab Emirates Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Figure 25     United Arab Emirates Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

 

List of Tables

 

Table 1         GCC Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 2        GCC Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 3        GCC Erectile Dysfunction Drugs Market Size, By Country, By Value, 2019−2029

Table 4        Bahrain Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 5         Bahrain Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 6         Kuwait Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 7         Kuwait Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 8        Oman Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 9        Oman Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 10      Qatar Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 11      Qatar Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 12      Saudi Arabia Erectile Dysfunction Drugs Market Size, By Product, By Value, 2019−2029

Table 13      Saudi Arabia Erectile Dysfunction Drugs Market Size, By Distribution Channel, By Value, 2019−2029

Table 14      United Arab Emirates Erectile Dysfunction Drugs Market Size, By Value (USD Million), 2019−2029

Table 15      United Arab Emirates Erectile Dysfunction Drugs Market Share, By Product, By Value, 2019−2029

Table 16      United Arab Emirates Erectile Dysfunction Drugs Market Share, By Distribution Channel, By Value, 2019−2029

Table 17      Pfizer Company Overview

Table 18      Pfizer Financial Overview

Table 19      Eli Lilly and Company: Company Overview

Table 20      Eli Lilly and Company Financial Overview

Table 21      Teva Company Overview

Table 22      Teva Financial Overview

Table 23      Sun Pharmaceutical Company Overview

Table 24      Sun Pharmaceutical Financial Overview

Table 25      Lupin Limited Company Overview

Table 26      Lupin Limited Financial Overview

Table 27      Glenmark Pharmaceuticals Limited Company Overview

Table 28      Glenmark Pharmaceuticals Limited Financial Overview

Table 29      Cipla Ltd Company Overview

Table 30      Cipla Ltd Financial Overview

Table 31      Sanofi Company Overview

Table 32      Sanofi Financial Overview

Table 33      Apricus Biosciences Company Overview

Table 34      Apricus Biosciences Financial Overview

Table 35      Bayer AG Company Overview

Table 36      Bayer AG Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Saudi Arabia is expected to grow at the fastest rate in the GCC Erectile Dysfunction Drugs Market during the forecast period between 2023 and 2029.
Ans: The retail pharmacies segment held the highest market share in the GCC Erectile Dysfunction Drugs Market by distribution channel.
Ans: GCC Erectile Dysfunction Drugs Market size was estimated at USD 68.83 million in 2022.
Ans: Major factors driving the growth of GCC Erectile Dysfunction Drugs Market include growth in embracing poor lifestyle choices and rising prevalence of erectile dysfunction.
Ans: Key players in GCC Erectile Dysfunction Drugs Market include Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, and Bayer AG.